Chronic Kidney Disease Management

Introduction to CKD Management

• The American College of Cardiology recommends SGLT2 inhibitors as foundational first-line therapy for all CKD patients with eGFR ≥20 mL/min/1.73 m², combined with RAS inhibition and statin therapy for kidney and cardiovascular protection 1

Step 1: Initiate SGLT2 Inhibitors

• SGLT2 inhibitors, such as Canagliflozin 100 mg daily or Dapagliflozin 10 mg daily, are mandatory first-line therapy for all CKD patients, regardless of diabetes status, with eGFR ≥20 mL/min/1.73 m² 1, 2
• The National Kidney Foundation recommends continuing SGLT2 inhibitors even as eGFR declines below 20 mL/min/1.73 m² until dialysis initiation or transplantation 1, 3

Step 2: Add RAS Inhibition for Blood Pressure and Proteinuria Control

• The American Heart Association recommends ACE inhibitors or ARBs for CKD patients with albuminuria ≥30 mg/24 hours, with a target blood pressure of ≤130/80 mmHg 4, 5, 6
• The American College of Cardiology recommends titrating ACE inhibitors or ARBs to maximum tolerated dose for optimal kidney and cardiovascular protection 1

Step 3: Add Statin Therapy for Cardiovascular Protection

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend statin therapy for all CKD patients ≥50 years, with a moderate-to-high intensity dosing regimen, such as Atorvastatin 40-80 mg daily or Rosuvastatin 20-40 mg daily 7, 1

Step 4: Consider Advanced Kidney Protection

• The European Renal Association recommends considering nonsteroidal mineralocorticoid receptor antagonists, such as Finerenone, for additive kidney and cardiovascular protection beyond SGLT2 inhibitors and RAS blockade 1

Step 5: Implement Mandatory Lifestyle Modifications

• The American Heart Association recommends sodium restriction to <2 g per day, protein intake of 0.8 g/kg body weight per day, and a target BMI of 20-25 kg/m² through weight management 4, 5, 6, 1

Step 6: Manage CKD-Specific Complications

• The National Kidney Foundation recommends monitoring hemoglobin regularly and treating anemia with iron supplementation before or with erythropoiesis-stimulating agents 1

Step 7: Cardiovascular Disease Prevention

• The American College of Cardiology recommends aspirin 81 mg daily for lifelong secondary prevention in CKD patients with established cardiovascular disease, with a class 1C recommendation 7, 1

Step 8: Monitoring Schedule

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend regular reassessment every 3-6 months, including eGFR, serum creatinine, electrolytes, urine albumin-to-creatinine ratio, hemoglobin, blood pressure, and lipid panel 1, 6

Step 9: Nephrology Referral Criteria

• The American Society of Nephrology recommends immediate referral to nephrology when eGFR <30 mL/min/1.73 m², with persistent electrolyte abnormalities or uncontrolled hypertension despite multiple agents 1, 2

Special Considerations for Diabetes and CKD

• The American Diabetes Association recommends SGLT2 inhibitors as first-line therapy for both glycemic control and kidney protection in CKD patients with diabetes, with metformin as an alternative if eGFR ≥30 mL/min/1.73 m² 2

Critical Medications to AVOID in CKD

• The National Kidney Foundation recommends avoiding NSAIDs, metformin when eGFR <30 mL/min/1.73 m², and sulfonylureas due to increased risk of acute kidney injury, lactic acidosis, and hypoglycemia 1, 4, 3, 2